Table 3 Reproductive outcomes
Cabergoline group (n = 118) | Antagonist rescue combined with cabergoline group (n = 118) | Odd ratio (95 % CI) | P value | |
|---|---|---|---|---|
Clinical pregnancy/started cycle | 42/118(35.59 %) | 46/118(38.98 %) | 0.87[0.51–1.47] | 0.59 |
Clinical pregnancy/transfer cycle | 42/114(36.84 %) | 46/118(38.98 %) | 0.91[0.54–1.55] | 0.74 |
Ongoing pregnancy/started cycle | 37/118(31.36 %) | 41/118(34.75 %) | 0.86[0.5–1.48] | 0.578 |
Ongoing pregnancy/transfer cycle | 37/114(32.46 %) | 41/118(34.75 %) | 0.9[0.52–1.56] | 0.708 |
Implantation rate | 49/265(18.49 %) | 53/267(19.85 %) | 0.92[0.59–1.41] | 0.689 |
Multiple pregnancy rate | 7/42(16.67 %) | 6/46(13.04 %) | 1.33[0.41–4.34] | 0.632 |
Spontaneous abortion rate | 5/42(11.9 %) | 5/46(10.87 %) | 1.11[0.3–4.14] | 0.879 |